Nugenerex Immuno-Oncology Inc represents a commitment to advancing immunotherapy solutions for cancer treatment. The company aims to leverage scientific innovation to develop effective and personalized therapies that can improve patient outcomes. With a focus on immuno-oncology, Nugenerex Immuno-Oncology Inc strives to harness the power of the immune system to target and eradicate cancer cells. By combining cutting-edge research, clinical expertise, and a patient-centric approach, the company is dedicated to making significant contributions to the field of cancer immunotherapy. Nugenerex Immuno-Oncology Inc's corporate philosophy centers around driving scientific advancements, fostering collaboration, and ultimately helping patients in their fight against cancer.

Nugenerex Immuno-Oncology Inc is primarily present in the United States.

Nugenerex Immuno-Oncology Inc has achieved several significant milestones. The company successfully completed Phase II clinical trials for their cancer immunotherapy product, demonstrating promising results in treating various forms of cancer. Additionally, Nugenerex received FDA approval for its groundbreaking treatment, which has shown to improve patient outcomes and quality of life. Furthermore, the company has expanded its global reach by establishing strategic collaborations with renowned research institutions and pharmaceutical companies. Nugenerex's dedication to innovation and advancements in immuno-oncology has made it a leader in the field, offering hope for patients and revolutionizing cancer treatment.

Nugenerex Immuno-Oncology Inc is a biotechnology company specializing in immunotherapy treatments for cancer. Founded in [insert year], the company has emerged as a leading player in the field, harnessing the power of the immune system to combat various types of cancer effectively. Over the years, Nugenerex Immuno-Oncology Inc has dedicated its efforts to developing innovative therapies, focusing on personalized cancer treatments to increase patient outcomes and improve quality of life. With a team of experienced scientists and researchers, the company has made significant advancements in the field, positioning itself as a key contender in the fight against cancer. Nugenerex Immuno-Oncology Inc's commitment to groundbreaking research and development continues to shape the future of cancer treatment.

The main competitors of Nugenerex Immuno-Oncology Inc in the market are companies like Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Novartis AG, and Pfizer Inc.

Nugenerex Immuno-Oncology Inc is primarily active in the healthcare and biotechnology industries.

The business model of Nugenerex Immuno-Oncology Inc is focused on developing and commercializing innovative immunotherapies for the treatment of cancer. The company utilizes a proprietary technology platform that combines tumor-specific immune stimulation with targeted drug delivery to enhance the patient's immune system's ability to recognize and destroy cancer cells. Nugenerex Immuno-Oncology Inc aims to provide personalized and effective cancer treatment options by leveraging its expertise in immunotherapy and advancing its pipeline of novel therapies. With a strong commitment to research and development, the company strives to revolutionize the field of oncology and improve patient outcomes in the fight against cancer.

KGV za Nugenerex Immuno-Oncology trenutno se ne može izračunati.

KUV trenutno ne može biti izračunat za Nugenerex Immuno-Oncology.

AlleAktien Qualitätsscore za Nugenerex Immuno-Oncology je 2/10.

Prihod trenutno ne može biti izračunat za Nugenerex Immuno-Oncology.

Dobit trenutno ne može biti izračunata za Nugenerex Immuno-Oncology.

Nugenerex Immuno-Oncology Inc is a company specialized in researching, developing, and commercializing immunotherapeutic products for cancer treatment. The company utilizes groundbreaking technologies to develop new approaches for cancer immunotherapy and improve medicine. The company has several divisions, including research and development, clinical trials, and business development. Research and development focus on identifying and developing novel cancer therapies based on the principles of immuno-oncology. Clinical trials conduct evaluations to assess the efficacy and safety of these novel immunotherapies. Business development works closely with other companies to ensure that the company's products are marketed and distributed to as many patients as possible. Nugenerex Immuno-Oncology Inc specializes in the development of antigen-specific immunotherapies, including T-cell receptor (TCR)-based therapies and peptide vaccine vectors. These immunotherapies aim to enhance the body's defense mechanisms against cancer by stimulating the immune system to target and eliminate cancer cells. The drugs target specifically identified tumor antigens, allowing for highly effective targeted treatment of cancer. The company already has several innovative products in its pipeline, including NGT016R, NGT017R, NGT019R, and NGT020R. NGT016R is a TCR product for the treatment of melanoma, NGT017R is a TCR product for the treatment of gastric cancer, and NGT019R is a peptide vaccine vector product for the treatment of glioblastoma. Nugenerex Immuno-Oncology Inc's immunotherapy products are an important advancement in the development of cancer therapies and show promising results in clinical trials. The company has established partnerships with pharmaceutical and biotechnology companies worldwide to expand its product pipeline. This has helped the company develop new technologies and treatments to make cancer immunotherapy even more powerful and effective. Nugenerex Immuno-Oncology Inc also collaborates closely with institutions of medical advancement, hospitals, and universities to advance research and development in cancer immunotherapy. Overall, Nugenerex Immuno-Oncology Inc has revolutionized immuno-oncology and provides patient-specific, personalized therapies to offer a better prognosis for cancer patients. Through partnerships with other companies and institutions, the company can accelerate the development and commercialization of new cancer therapies and reach more affected individuals.

Nugenerex Immuno-Oncology isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Nugenerex Immuno-Oncology trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Nugenerex Immuno-Oncology je US67053X1028.

WKN od Nugenerex Immuno-Oncology je A2P853.

Oznaka burze tvrtke Nugenerex Immuno-Oncology je NUGX.

U posljednjih 12 mjeseci Nugenerex Immuno-Oncology je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Nugenerex Immuno-Oncology će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Nugenerex Immuno-Oncology iznosi .

Nugenerex Immuno-Oncology isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Nugenerex Immuno-Oncology je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Nugenerex Immuno-Oncology se pripisuje sektoru '—'.

Da bi primili posljednju dividendu od Nugenerex Immuno-Oncology od 18. 11. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 18. 11. 2024..

Posljednja isplata dividende izvršena je 18. 11. 2024..

U godini 2023 su od Nugenerex Immuno-Oncology 0 USD isplaćene kao dividende.

Dividende od Nugenerex Immuno-Oncology isplaćuju se u USD.